Table 2 Changes in biochemical parameters and microcirculation from baseline to 12 weeks after the administration of rosuvastatin (20 mg daily) in patients with type 2 diabetes and dyslipidemia
Parameters | Baseline | At 12Â weeks | P |
|---|---|---|---|
BMI (kg/m2) | 24.6 ± 2.8 | 24.8 ± 2.7 | 0.114 |
Total cholesterol (mg/dL) | 233.4 ± 36.5 | 132.7 ± 28.7 | < 0.001 |
Triglycerides (mg/dL) | 230.5 ± 95.8 | 151.1 ± 69.6 | 0.002 |
Triglycerides at 2 h during MMT (mg/dL) | 298.6 ± 128.4 | 186.3 ± 78.0 | < 0.001 |
HDL-cholesterol (mg/dL) | 42.4 ± 5.2 | 44.7 ± 6.2 | 0.041 |
LDL-cholesterol (mg/dL) | 147.2 ± 26.5 | 68.3 ± 24.5 | < 0.001 |
Fasting plasma glucose (mg/dL) | 173.8 ± 63.9 | 152.4 ± 60.9 | 0.081 |
Postprandial 2 h glucose (mg/dL) | 282.0 ± 97.1 | 264.2 ± 102.7 | 0.489 |
HbA1c (%) | 8.3 ± 2.0 | 8.0 ± 1.8 | 0.559 |
Fasting plasma insulin (μIU/L) | 10.3 ± 4.9 | 14.1 ± 17.4 | 0.282 |
HOMA-IR | 4.3 ± 2.2 | 5.1 ± 5.9 | 0.486 |
HOMA-β | 44.8 ± 27.4 | 80.0 ± 98.6 | 0.110 |
AST (IU/mL) | 25.3 ± 11.1 | 30.8 ± 19.1 | 0.100 |
ALT (IU/mL) | 32.3 ± 22.4 | 35.8 ± 21.7 | 0.348 |
Creatinine (mg/mL) | 0.81 ± 0.18 | 0.80 ± 0.10 | 0.713 |
hsCRP (mg/dL)b | 0.47 ± 1.40 | 0.10 ± 0.09 | 0.014 |
ADMA (mmol/L) | 432.0 ± 48.7 | 415.3 ± 51.6 | 0.040 |
ADMA at 2 h during MMT (mmol/L) | 458.3 ± 42.2 | 419.0 ± 49.4 | < 0.001 |
PON-1 (μg/mL) | 11.9 ± 2.2 | 12.6 ± 2.5 | 0.066 |
PON-1 at 2 h during MMT (μg/mL) | 10.6 ± 1.4 | 12.5 ± 2.2 | 0.001 |
Microvascular reactivity using laser Doppler flowmetry | |||
 Increase after ischemic challenge (%) | 335.3 ± 123.4 | 402.7 ± 133.4 | 0.006 |